Yubrine Moraa Gachemba: BETULA Adds New Evidence for Catheter-Directed Thrombolysis in PE
Yubrine Moraa Gachemba, Consultant Cardiologist at The Nairobi Hospital, shared EuroIntervention‘s post on LinkedIn:
“Pulmonary embolism care is entering a more nuanced era.
BETULA adds important randomized evidence that carefully selected patients with intermediate-high-risk PE may achieve earlier right ventricular unloading with low-dose, short-duration catheter-directed thrombolysis, without an observed increase in major bleeding.
But the larger question is not simply whether we can intervene earlier. It is which patients derive meaningful clinical benefit, at what risk, and within which health systems.
For Africa and the wider Global South, this matters enormously. Innovation in PE care must be accompanied by better risk stratification, multidisciplinary decision-making, appropriate imaging, and equitable access to reperfusion strategies.
The future of PE management will not be anticoagulation versus intervention. It will be precision in selecting the right patient, for the right therapy, at the right time.
Important data – and an evolving space to watch.”
EuroIntervention shared a post on LinkedIn about a recent article by Jacob Schultz et al., adding:
“In the randomised BETULA trial, low-dose, short-duration catheter-directed thrombolysis improved early right ventricular unloading compared with anticoagulation alone in patients with intermediate-high-risk pulmonary embolism, without increasing major bleeding.”
Title: Low-dose, short-duration catheter-directed thrombolysis for acute intermediate-high-risk pulmonary embolism: the BETULA trial
Authors: Jacob Schultz, Gro Egholm, Mikael Kjær Poulsen, Bo Løfgren, Morten Würtz, Hanne Maare Søndergaard, Mads Jønsson Andersen, Jacob Valentin Hansen, Gratien Andersen, Shifan Thangavel, Søren Mellemkjær, Anushree Burade, Mannudeep Kalra, Jens Erik Nielsen-Kudsk, Asger Andersen
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC
-
Oct 16, 2026, 12:17Exploring Endothelial Cells, Genetic Fate Mapping, and Revascularization – ISTH
-
Oct 16, 2026, 10:07Habib Bennaceur: Building a Stronger Care Pathway for Sickle Cell Disease in India
-
Oct 16, 2026, 09:59Tareq Abadl: A Simple Guide to Blood Collection Tubes
-
Oct 16, 2026, 09:50Mona Alfaraj: Distinguishing HCL from SMZL in Bone Marrow